Praluent vs Losartan: Switching Between Them

Why These Two Drugs Get Compared

Patients managing multiple cardiometabolic risk factors often take both a lipid-lowering agent and an antihypertensive. Alirocumab (Praluent) and losartan occupy separate pharmacologic categories: alirocumab is a monoclonal antibody targeting PCSK9 to reduce LDL cholesterol by 50 to 60% beyond statin therapy, while losartan is an oral ARB that reduces blood pressure by blocking the angiotensin II type-1 receptor. They are not interchangeable.

The comparison arises when clinicians reassess a patient's treatment plan. A post-acute coronary syndrome (ACS) patient might be started on alirocumab for aggressive LDL-C lowering, while losartan is added later if hypertension develops or if renal protection becomes a priority. Conversely, a patient stable on losartan for years may need alirocumab added after an LDL-C level remains above goal despite maximally tolerated statin therapy. The 2018 AHA/ACC cholesterol guidelines recommend PCSK9 inhibitors for patients with ASCVD whose LDL-C remains ≥70 mg/dL on maximally tolerated statin plus ezetimibe. The question of "switching" between these agents is really a question about adjusting the overall cardiometabolic regimen rather than performing a 1:1 drug swap.

Mechanism of Action: Two Completely Different Targets

Alirocumab binds to PCSK9, a protein that degrades LDL receptors on hepatocytes. By blocking PCSK9, alirocumab increases the number of LDL receptors available to clear LDL-C from the bloodstream. The result is a rapid, pronounced drop in circulating LDL cholesterol. In ODYSSEY OUTCOMES (N=18,924), patients receiving alirocumab 75 mg every two weeks (uptitrated to 150 mg as needed) achieved a mean LDL-C of 53.3 mg/dL at 48 months compared to 101.4 mg/dL in the placebo group, a 54.7% relative reduction [1].

Losartan works through an entirely different pathway. It selectively blocks the angiotensin II type-1 (AT1) receptor, preventing angiotensin II from causing vasoconstriction, aldosterone secretion, and sodium retention. This lowers blood pressure. In the LIFE trial (N=9,193), losartan-based treatment produced a 13% reduction in the primary composite endpoint (cardiovascular death, stroke, or myocardial infarction) versus atenolol-based treatment, with a particularly strong 25% reduction in fatal and non-fatal stroke (HR 0.75, P=0.001) [2].

No shared molecular target exists. One drug clears cholesterol. The other relaxes blood vessels.

Clinical Trial Evidence Side by Side

Both drugs carry strong cardiovascular outcomes data, but from entirely different populations and comparators.

ODYSSEY OUTCOMES enrolled patients 1 to 12 months after an acute coronary syndrome event who had LDL-C ≥70 mg/dL (or non-HDL-C ≥100 mg/dL, or apolipoprotein B ≥80 mg/dL) despite high-intensity or maximally tolerated statin therapy. The primary endpoint was a composite of coronary heart disease death, nonfatal myocardial infarction, fatal or nonfatal ischemic stroke, or unstable angina requiring hospitalization. Alirocumab reduced this composite by 15% (HR 0.85 to 95% CI 0.78 to 0.93, P<0.001) over a median 2.8 years of follow-up [1]. An exploratory analysis showed an absolute 0.6% reduction in all-cause mortality in patients with baseline LDL-C ≥100 mg/dL.

The LIFE trial enrolled hypertensive patients aged 55 to 80 with electrocardiographic evidence of left ventricular hypertrophy (LVH). Over a mean 4.8 years, losartan-based therapy reduced the primary composite endpoint by 13% versus atenolol (HR 0.87, P=0.021) [2]. Blood pressure reduction was similar between groups (approximately 30/17 mmHg), suggesting losartan's benefit extended beyond blood pressure lowering alone.

Dr. Christie Ballantyne, Chief of Cardiology at Baylor College of Medicine, has noted: "Cardiometabolic risk is multifactorial. Optimizing both lipids and blood pressure produces risk reductions that are additive, not redundant."

These trials cannot be compared head to head. Different patient populations, different comparators, different endpoints. What they share is a consistent signal: treating each specific risk factor (elevated LDL-C and hypertension with LVH, respectively) reduces cardiovascular events.

When a Clinician Might Adjust Between These Agents

The word "switching" implies replacing one with the other. That framing is misleading here. Because alirocumab and losartan target different risk factors, the clinical scenarios usually involve adding or removing one while maintaining the other. True substitution would only make sense if a patient's primary risk factor changed.

Scenario 1: Adding alirocumab to an existing losartan regimen. A patient stable on losartan 100 mg for hypertension experiences an ACS event. Post-event, their LDL-C is 95 mg/dL despite rosuvastatin 40 mg plus ezetimibe 10 mg. Per 2018 ACC/AHA guidelines, a PCSK9 inhibitor is appropriate. Losartan continues unchanged [3].

Scenario 2: Adding losartan to an existing alirocumab regimen. A patient on alirocumab for familial hypercholesterolemia develops hypertension or is diagnosed with type 2 diabetic nephropathy, where ARBs have demonstrated renal protective effects [4]. Alirocumab continues; losartan is added.

Scenario 3: Discontinuing one agent. A patient achieves sustained LDL-C <55 mg/dL on alirocumab and a physician determines the statin-ezetimibe backbone alone could maintain goal. Alirocumab may be stopped. Losartan continues for blood pressure. Alternatively, if blood pressure normalizes through weight loss (for instance, via GLP-1 therapy), losartan may be deprescribed while alirocumab remains.

The ACC's 2019 primary prevention guidelines emphasize a "risk-based" approach where each drug addresses a distinct, measurable target. Dr. Robert Eckel, past president of the AHA, has stated: "You don't swap a statin for an antihypertensive. You layer therapies based on individual risk factor burden."

Practical Pharmacologic Considerations for Transitions

There are no known drug interactions between alirocumab and losartan. They can be started or stopped independently without a cross-taper. Each drug's pharmacokinetics supports clean transitions.

Alirocumab has a half-life of 17 to 20 days at steady state. After discontinuation, LDL-C returns to baseline within 4 to 8 weeks as PCSK9 levels recover and LDL receptor expression decreases [5]. No rebound phenomenon (LDL-C exceeding pre-treatment levels) has been documented. If restarting alirocumab after a gap, clinicians typically resume at 75 mg every 2 weeks and reassess LDL-C at 4 to 8 weeks.

Losartan has a much shorter half-life (approximately 2 hours for the parent compound, 6 to 9 hours for its active metabolite EXP3174). Blood pressure effects dissipate within 24 to 48 hours of the last dose. When stopping losartan, abrupt discontinuation is generally safe (unlike beta-blockers, ARBs carry no withdrawal rebound risk). When starting losartan, the typical initial dose is 50 mg daily, titrated to 100 mg daily based on blood pressure response [2].

Because the two drugs have no overlapping metabolism through CYP enzymes (losartan is metabolized by CYP2C9 and CYP3A4, while alirocumab is degraded through target-mediated clearance), simultaneous administration poses no pharmacokinetic concern.

Side Effect Profiles: What to Expect from Each

The side effect profiles differ substantially, reflecting their distinct mechanisms.

Alirocumab's most common adverse effect is injection site reactions, occurring in roughly 7% of patients in ODYSSEY OUTCOMES versus 5% with placebo [1]. Other reported effects include nasopharyngitis, influenza-like symptoms, and myalgia. There was initial concern about very low LDL-C levels (below 25 mg/dL), but long-term follow-up has not shown increased neurocognitive events or other harms at these levels. The EBBINGHAUS substudy (N=1,974) confirmed no difference in cognitive function between alirocumab and placebo groups over a median of 2.5 years of follow-up [6].

Losartan side effects tend to be mild. Dizziness occurs in about 3% of patients. Hyperkalemia is a class-wide ARB risk, particularly in patients with chronic kidney disease or those taking potassium-sparing diuretics. The LIFE trial reported cough rates similar to placebo (confirming losartan's advantage over ACE inhibitors on this endpoint) [2]. Rare reports of angioedema exist, though at lower rates than with ACE inhibitors. Losartan is contraindicated in pregnancy due to fetal toxicity.

A patient tolerating one of these drugs well has no pharmacologic reason to expect problems with the other.

Cost and Access Differences

This is where practical barriers often drive clinical decisions. Generic losartan costs $4 to $15 per month at most pharmacies, placing it among the most affordable cardiovascular medications available [7]. Insurance coverage is universal.

Praluent (alirocumab) carries a list price of approximately $450 per month after manufacturer price reductions in 2019. Prior authorization is required by nearly all payers. The ACC/AHA guidelines recommend a "clinician-patient discussion" about cost and adherence before initiating PCSK9 inhibitors [3]. Manufacturer copay assistance programs can reduce out-of-pocket costs to $0 for commercially insured patients, though Medicare Part D patients face different cost-sharing structures.

This 30-fold cost difference means that cost alone never drives a "switch" between these agents. A physician would not replace an expensive PCSK9 inhibitor with a cheap ARB (or vice versa) because they treat different conditions. The cost discussion matters most when deciding whether to add alirocumab to a regimen that already includes losartan and statins.

Who Should Take Both?

The highest-risk cardiometabolic patients may benefit from both drugs simultaneously. The profile includes patients with established atherosclerotic cardiovascular disease (ASCVD), LDL-C above target despite maximally tolerated statin plus ezetimibe, and co-existing hypertension (particularly with left ventricular hypertrophy or diabetic nephropathy).

The 2019 ACC/AHA primary prevention guidelines frame cardiovascular risk reduction as cumulative: each treated risk factor contributes an independent, additive benefit [8]. A patient whose 10-year ASCVD risk exceeds 20% and who has both uncontrolled LDL-C and uncontrolled blood pressure could see meaningful absolute risk reduction from addressing both simultaneously.

The RENAAL trial (N=1,513) demonstrated that losartan reduced the risk of doubling of serum creatinine by 25% (P=0.006) in patients with type 2 diabetes and nephropathy [4]. Patients with this renal indication plus residual LDL-C elevation represent a clear population for dual therapy.

Coordinating both agents requires monitoring LDL-C (fasting lipid panel 4 to 8 weeks after alirocumab initiation), blood pressure (at every visit), potassium levels (within 2 weeks of losartan initiation in CKD patients), and renal function (baseline and periodic creatinine/eGFR checks with losartan).

Monitoring Schedule When Using Both Agents

For patients on both alirocumab and losartan, a reasonable monitoring cadence includes: fasting lipid panel at 4 to 8 weeks after starting or adjusting alirocumab dose, then every 3 to 6 months; blood pressure at each clinical visit; serum potassium and creatinine at baseline, 1 to 2 weeks after losartan initiation, and then every 6 to 12 months; and hepatic function if clinical concern arises. The Endocrine Society's lipid management guidelines recommend LDL-C checks at 4 to 12 weeks after PCSK9 inhibitor dose changes [9].

Neither drug requires therapeutic drug level monitoring. Alirocumab efficacy is confirmed by LDL-C response. Losartan efficacy is confirmed by blood pressure readings and, in nephropathy patients, by urine albumin-to-creatinine ratio trends.